abstract |
The present invention relates to antibodies that specifically bind to BAFF receptor (BAFFR). More specifically, the present invention relates to antibodies that are BAFFR antagonists with B cell depleting activity in vivo, and pathological disorders that can be treated by death or depletion of B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmunity. A composition and a method of use for said antibody for treating a disease or lymphoma, leukemia and myeloma. |